New modeling study: QALY-based cost-effectiveness analyses undervalue life-extending Duchenne muscular dystrophy treatments, favoring delayed progression over mortality gains and highlighting limitations of traditional value frameworks. #HEOR #qalys #musculardystrophy jheor.org/article/156118